摘要
目的:分析麝香保心丸联合降脂药治疗冠心病的临床疗效。方法:选取2019年5月至2021年5月期间在洛阳伊洛医院就诊治疗的冠心病患者214例,根据随机数字表法将患者分为观察组和对照组,每组107例。对照组患者给予非诺贝特、瑞舒伐他汀治疗,观察组患者在对照组基础上加麝香保心丸治疗,比较两组患者治疗前后的血脂指标、炎症指标、肝肾功能变化情况。结果:治疗后,两组患者外周血总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL–C)水平均低于治疗前,高密度脂蛋白胆固醇(HDL–C)高于治疗前,且观察组患者外周血TC、TG、LDL–C水平均低于对照组,HDL–C水平高于对照组,差异具有统计学意义(P <0.05);治疗后,两组患者血清炎症因子水平均较治疗前下降,且观察组患者血清炎症因子水平均明显低于对照组,差异具有统计学意义(P <0.05);两组患者治疗前后肝肾功能指标比较,差异无统计学意义(P> 0.05)。结论:麝香保心丸联合降脂药治疗可有效改善冠心病患者血脂代谢异常,减轻其炎症反应,具有较高的安全性。
Objective To analyze the clinical efficacy of Shexiang Baoxin Pill combined with lipid-lowering drugs in the treatment of coronary heart disease.Methods A total of 214 patients with coronary heart disease who were treated in Luoyang Yiluo Hospital from May 2019 to May 2021 were selected and divided into an observation group and a control group according to random number table method,with 107 patients in each group.The control group was treated with fenofibrate and rosuvastatin,while the observation group was treated with Shexiang Baoxin Pill on the basis of the control group. The changes of blood lipid indicators, inflammation indicators, and liver and kidney function were compared between the two groups before and after treatment. Results After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein-cholesterol (LDL-C) in the both groups were lower than those before treatment, while the level of high density lipoprotein-cholesterol (HDL-C) was higher than that before treatment, the levels of TC, TG and LDL-C in the observation group were lower than those in the control group, and the level of HDL-C in the observation group was higher than that in the control group, the differences were statistically significant (P < 0.05). The levels of inflammatory factors in the both groups were significantly lower than those before treatment, and the levels of inflammatory factors in the observation group were significantly lower than those in the control group , the differences were statistically significant (P < 0.05). There was no significant difference in the levels of liver and kidney function between the two groups before and after treatment (P > 0.05). Conclusion Shexiang Baoxin Pill combined with lipid-lowering drugs can effectively improve the abnormal metabolism of blood lipids and reduce the inflammatory reaction in patients with coronary heart disease, with high safety.
作者
宋利
刘飞飞
梁艳艳
SONG Li;LIU Feifei;LIANG Yanyan(Luoyang Yiluo Hospital,Henan Luoyang 471000)
出处
《深圳中西医结合杂志》
2023年第13期37-40,共4页
Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词
冠心病
麝香保心丸
非诺贝特
瑞舒伐他汀
Coronary heart disease
Shexiang Baoxin Pill
Fenofibrate
Rosuvastatin
